Chao Sun MD,Suying Feng MD
doi : 10.1111/ijd.15589
Volume 60, Issue 12 p. 1441-1448
Bullous pemphigoid (BP) is a common autoimmune bullous disease which mainly affects the elderly. The incidence of BP is gradually increasing and associated with high mortality. This disease is clinically characterized by intensely pruritic and widespread bullous lesions. Alternative therapy options for pruritus in patients with BP are limited primarily because pathophysiological mechanisms of itching in BP are still unclear. This review aims to explain crucial concepts of the pathogenesis of pruritus in BP. Vital findings in recent years will be summarized, and cofactors of the pathogenesis of pruritus will be discussed in detail. We will summarize knowledge on pathogenic factors in the immunologic level conducing to skin pruritus in BP.
Roseane B. de Miranda MD,Patrícia Weimer MD,Rochele C. Rossi PhD
doi : 10.1111/ijd.15518
Volume 60, Issue 12 p. 1449-1461
Skin aging has become a recurring concern even for younger people, mainly owing to increased life expectancy. In this context, the use of nutricosmetics as supplements has increased in recent years. Moreover, numerous scientific studies have shown the benefits of hydrolyzed collagen supplementation in improving the signs of skin aging. The objective of this study was to summarize the evidence on the effects of hydrolyzed collagen supplementation on human skin through a systematic review followed by a meta-analysis of clinical trials focusing on the process of skin aging. A literature search was conducted in the Medline, Embase, Cochrane, LILACS (Latin American and Caribbean Health Sciences Literature), and Journal of Negative Results in BioMedicine databases. Eligible studies were randomized, double-blind, and controlled trials that evaluated oral supplementation with hydrolyzed collagen as an intervention and reported at least one of the following outcomes: skin wrinkles, hydration, elasticity, and firmness. After retrieving articles from the databases, 19 studies were selected, with a total of 1,125 participants aged between 20 and 70?years (95% women). In the meta-analysis, a grouped analysis of studies showed favorable results of hydrolyzed collagen supplementation compared with placebo in terms of skin hydration, elasticity, and wrinkles. The findings of improved hydration and elasticity were also confirmed in the subgroup meta-analysis. Based on results, ingestion of hydrolyzed collagen for 90?days is effective in reducing skin aging, as it reduces wrinkles and improves skin elasticity and hydration.
Natalia Rendón-Serna BSc,Luis A. Correa-Londoño MD,Margarita M. Velásquez-Lopera MD, PhD,Maria Bermudez-Muñoz BSc, MSc, PhD
doi : 10.1111/ijd.15451
Volume 60, Issue 12 p. 1462-1480
Cutaneous T-cell lymphomas (CTCL) result from the infiltration and proliferation of a population of T cells in the skin, inducing changes in the activity of both T cells and surrounding skin cells. In the CTCL microenvironment, cell interactions mediated by cell signaling pathways are altered. Defining changes in cell signaling enables to understand T-cell deregulations in the CTCL microenvironment and thus the progression of the disease. Moreover, characterizing signaling networks activated in CTCL stages can lead to consider new molecular biomarkers and therapeutic targets. Focusing on mycosis fungoides (MF), the most frequent variant of CTCL, and Sézary syndrome (SS), its leukemic variant, this review highlights recent molecular and genetic findings revealing modifications of key signaling pathways involved in (1) cell proliferation, cell growth, and cell survival such as MAP kinases and PI3K/Akt; (2) immune responses derived from TCR, TLR, JAK/STAT, and NF-kB; and (3) changes in tissue conditions such as extracellular matrix remodeling, hypoxia, and angiogenesis. Alterations in these signaling networks promote malignant T-cell proliferation and survival, T-cell migration, inflammation, and suppression of immune regulation of malignant T cells, making a skin microenvironment that allows disease progression. Targeting key proteins of these signaling pathways, using molecules already available and used in research, in clinical trials, and with other disease indications, can open the way to different therapeutic options in CTCL treatment.
Mandy Majidian BA,Hiren Kolli BS,Ronald L. Moy MD
doi : 10.1111/ijd.15541
Volume 60, Issue 12 p. 1481-1487
Hormone replacement therapy and various devices exist to treat signs of aging, such as skin thinning, yet there are no reviews summarizing or evaluating their role in neocollagenesis and the associated increase in skin thickness.
Rabi I. Ekore MBBS(IB), MPE, MSc (CAMH), FWACP,John O. Ekore PhD
doi : 10.1111/ijd.15587
Volume 60, Issue 12 p. 1488-1493
A plethora of health-related concerns, including skin disorders, are particularly common during the critical periods of adolescence and young adulthood. Their reactions to skin-related disorders can be different from their reactions to other disorders. While medical problems could be physiologically impacting, skin disorders like excoriation disorder can, in addition, directly affect their physical appearance in ways that have psychological consequences like anxiety, low self-esteem, and impaired quality of life. The increasing prevalence of excoriation disorder has resulted in its inclusion in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the eleventh edition of the International Classification of Diseases (ICD-11) manuals as one of the obsessive–compulsive disorders (OCD)-related disorders. However, health care professionals may not often recognize this important entity especially among adolescents and young adults with acne vulgaris presenting with chronic or recurrent acne-induced postinflammatory hyperpigmentation and scars. A number of self-reported tools are available for use in screening and/or assessment of excoriation disorder and to aid its management. While both pharmacologic and non-pharmacologic therapies are available, patient education is important. Physicians who usually make first contact with patients, such as Family Medicine Physicians, Pediatricians, Dermatologists, and Aesthetic Medicine Physicians, should have a relatively high index of suspicion for this disorder, especially in those presenting rather frequently with new or repeat lesions. Prompt referral to licensed mental health specialists is encouraged in order to ensure the provision of holistic care to affected persons.
Georgia Kyriakou MD, MSc, cPhD,Asimoula Kyriaki MD,Eleni P. Kourea MD, PhD,Stelios F. Assimakopoulos MD, PhD,Christina Magkou MD,Sophia Georgiou MD, PhD
doi : 10.1111/ijd.15612
Volume 60, Issue 12 p. 1494-1496
Asma Toumi MD,Noureddine Litaiem MD,Soumaya Gara MD,Ines Chabchoub MD,Takwa Bacha MD,Maroua Slouma MD,Lamia Ben Hassine MD,Soumaya Rammeh MD,Meriem Jones MD, PhD,Faten Zeglaoui MD
doi : 10.1111/ijd.15685
Volume 60, Issue 12 p. 1497-1503
Macrocheilia is an inflammatory disfiguring condition responsible for the swelling of the lips. This multi-etiological entity represents a diagnostic and therapeutic challenge. Published data on macrocheilia is scarce, often limited to granulomatous cheilitis.
Lei Wang MM,Junshen Wu MM,Zhibing Dai MM,Suzhi Ji MM,Renbing Jiang PhD
doi : 10.1111/ijd.15642
Volume 60, Issue 12 p. 1504-1509
Acral lentiginous melanoma (ALM) is common in China with poor prognosis. However, there are only a few studies of ALM in the Asian population. We aimed to summarize and analyze the clinical characteristics, treatment strategy, treatment effect, and prognostic factors of ALM in a Chinese population.
Ik Jun Moon MD, PhD,Keon Hee Lee MD,Jae Won Choi MD,Woo Jin Lee MD, PhD,Chong Hyun Won MD, PhD,Sungeun Chang MD, PhD,Jee Ho Choi MD, PhD,Mi Woo Lee MD, PhD
doi : 10.1111/ijd.15561
Volume 60, Issue 12 p. 1510-1519
Mycosis fungoides (MF) shows racial and regional differences in terms of clinical features. The availability of therapeutic options as well as drugs differs from one country to another. There are only limited data on the clinical characteristics and treatment experience of MF from South Korea.
Jordane Barbé MD,Claire Poreaux MD,Thomas Remen PhD,Amélie Schoeffler MD,Véronique Cloché MD,Jean-Luc Schmutz MD, PhD,Gabriela Escobar MD, MSc,Anne-Claire Busztejn MD, PhD
doi : 10.1111/ijd.15584
Volume 60, Issue 12 p. 1520-1528
Dupilumab is the first human monoclonal antibody approved for the treatment of atopic dermatitis (AD). Clinical trials have reported an increase of ocular side effects in patients who receive dupilumab, with a prevalence of 5–37%.
Daniel Cuestas MD, MSc,John Pedraza MD,Hugo Herrera MD,Adriana Motta MD,Andrés Cuestas Eng,Yency Forero MD,Ricardo Porras MD,Fernando Urrea MD,Dany Galvis MD,Ingrid Galvis MD,Maria-Alejandra Bernal MD,Maria-Victoria Alvarado MD,Rosa Bula MD,Oscar Velasquez MD,Dennys Villalba MD,Sergio Lamus MD,Gabriel Ariza MD,Natalia Bayona MD,Ana Gutierrez MD,Alexandra Segura MSc, PhD,Monica Patiño MD,Alejandra Perafan MD,Santiago Ramirez-Rodriguez MD,Mariam Rolon MD
doi : 10.1111/ijd.15672
Volume 60, Issue 12 p. 1529-1546
Cutaneous myiasis in patients with malignant wounds or skin cancer is a rare and undesirable event with limited epidemiological data. A subregister of reports, lack of education in the population, inadequate empirical treatments, and medical underestimation are components of a public health problem that threatens patients' lives.
Stefano Senatore MD,Roberto Maglie MD,Francesca Montefusco MD,Lavina Quintarelli MD,Adele Salemme BS,Giovanni Di Zenzo PhD,Emiliano Antiga MD, PhD
doi : 10.1111/ijd.15699
Volume 60, Issue 12 p. 1547-1549
Margaret E. Lang BS,Deenah N. Farrell BFA,Nneka I. Comfere MD,Martha Q. Lacy MD,Julio C. Sartori-Valinotti MD
doi : 10.1111/ijd.15636
Volume 60, Issue 12 p. 1550-1552
Chandraiah Madura MBBS, MD, FRGUHS,Preethi Balakrishna Nayak MBBS, MD, DNB, FRGUHS, FAGE,Pavan R. Raj MBBS, MD, FRGUHS,Byalakere Shivanna Chandrashekar MBBS, MD, DNB
doi : 10.1111/ijd.15761
Volume 60, Issue 12 p. 1553-1560
Ear keloids are benign, fibrous proliferations due to excessive collagen synthesis and deposition. It is a popular practice to pierce earlobes for decorative earrings and adornment; this might trigger the keloid process. Although there are varied treatment modalities, it is unsatisfactory and has always been a challenge. The aim is to evaluate the efficacy of surgical treatment with intralesional therapy in auricular keloids.
Parvathy Santhosh MD,Mamatha George MD
doi : 10.1111/ijd.15752
Volume 60, Issue 12 p. 1561-1565
Clascoterone is an androgen receptor inhibitor which has been approved by the United States Food and Drug Administration for the topical treatment of acne vulgaris in patients 12?years of age and older. It competes with androgens, especially dihydrotestosterone, for androgen-receptor binding and limits their binding, thus inhibiting downstream signaling of pathways involved in the pathogenesis of acne. It inhibits androgen receptor-regulated gene transcription, and antagonizes lipid and inflammatory cytokine production in a dose-dependent manner in human primary sebocytes. Clascoterone is commercially available as 1% (10?mg/g) cream. Adverse effects of topical clascoterone are mild and infrequent, and are mostly limited to local skin reactions. Long-term safety studies have shown an absence of systemic antiandrogenic effects like reduced libido or feminization in male participants. Clascoterone seems a promising topical drug with a novel mechanism of action that could be added to the armamentarium of therapies for acne.
Makoto Kondo MD, PhD,Asami Ito MD, PhD,Yoshiaki Matsushima MD,Shohei Iida MD,Ai Umaoka MD,Takehisa Nakanishi MD,Koji Habe MD, PhD,Hiroshi Imai MD, PhD,Keiichi Yamanaka MD, PhD
doi : 10.1111/ijd.15933
Volume 60, Issue 12 p. 1566-1567
Felipe Mardones MD,Karen Valenzuela MD
doi : 10.1111/ijd.15942
Volume 60, Issue 12 p. 1568-1569
Aditya K. Gupta MD, PhD,Maanasa Venkataraman MSc,Helen J. Renaud PhD,Richard Summerbell PhD,Neil H. Shear MD,Vincent Piguet MD, PhD
doi : 10.1111/ijd.15495
Volume 60, Issue 12 p. e474-e479
Antimicrobial stewardship (AMS) programs have been widely recognized among the public health community. These programs focus majorly on bacterial infections, efficient antibiotic use, and measures to curb increasing antibacterial resistance. AMS programs are successfully established around the globe; however, very few include antifungal stewardship (AFS). The increasing incidence of superficial and invasive fungal infections, combined with delayed or inaccurate diagnosis, has contributed to the overprescribing and overuse of antifungal agents. Such increased exposure to antifungal agents may be a reason for the emergence of increasing antifungal resistance among fungal pathogens. With mounting reports of treatment failures and resistant infections, the evidence to support the need for AFS programs is increasing. AFS is an emerging branch of AMS programs that requires global attention and recognition.
Frank Winsett MD,Kristyna Gleghorn MD,Julie Croley MD,Richard F. Wagner Jr. MD
doi : 10.1111/ijd.15540
Volume 60, Issue 12 p. e480-e485
Dermatologists are faced with an aging population, accompanied by an increase in the incidence of skin cancer, especially nonmelanoma skin cancer. With this increase in cutaneous malignancy comes an increase in the number of dermatologic procedures being performed. A common concern of dermatologists and dermatology patients is the attenuation and management of pain associated with dermatologic procedures. Fortunately, there are several techniques that may be used in the preoperative, intraoperative, and postoperative periods to manage patient anxiety, minimize injection pain, and safely and effectively treat postoperative pain.
Matthew L. Hrin BA,Arjun M. Bashyam BA,William W. Huang MD, MPH,Steven R. Feldman MD, PhD
doi : 10.1111/ijd.15539
Volume 60, Issue 12 p. e486-e492
Pyoderma gangrenosum is a rare neutrophilic dermatosis that is commonly treated with systemic corticosteroids; however, their potent side effects may warrant tapering, and non-steroidal systemic immunosuppressants may help maintain or bolster disease clearance during weaning. Although cyclosporine is regarded as a favorable corticosteroid-sparing agent, it is associated with several side effects, such as renal toxicity and hypertension, that may limit its feasibility. Mycophenolate mofetil is a well-tolerated alternative with limited data. Institutional review board approval was obtained to review patients from a single institution who received mycophenolate mofetil for pyoderma gangrenosum between January 1, 2010, and December 31, 2019. A systematic MEDLINE (PubMed) review was performed of articles containing linked keywords: “mycophenolate mofetil” and “pyoderma gangrenosum”. Patient demographics, presentation details, and treatment regimen characteristics were recorded. Fourteen of our pyoderma gangrenosum patients were treated with mycophenolate mofetil concomitantly with prednisone. Ninety-three percent of our patients achieved improvement within 12?months (mean 4.5?months), including five patients who experienced complete healing. Outcomes in literature patients were comparable; 77% either improved or maintained clearance with mycophenolate mofetil. Greater than 80% of total patients experienced healing or adequate disease control at a median dose of 2000?mg daily. The most common side effects of mycophenolate mofetil were myelosuppression and gastrointestinal upset, which were both seen in 18% of patients. Although this study is subject to publication bias, mycophenolate mofetil appears to be an efficacious and well-tolerated adjunctive therapy option for pyoderma gangrenosum.
Jacqueline R. Hwang BS,Alexander M. Cartron BS,Amor Khachemoune MD, FAAD, FACMS
doi : 10.1111/ijd.15615
Volume 60, Issue 12 p. e493-e499
Nigella sativa (N. sativa) is a widely used medicinal herb with a rich cultural and religious history in Unani, Ayurveda, Chinese, and Arabic medicine. N. sativa contains many natural bioactive agents including alkaloids, saponins, alpha-hederin, and thymoquinone that contribute to its broad range of benefits as a diuretic, bronchodilator, antihypertensive, antidiabetic, and analgesic. In addition, N. sativa possesses antimicrobial, anti-inflammatory, and antineoplastic effects, making it an interesting potential therapy for the treatment of dermatological conditions. This article reviews the current literature surrounding the pharmacological effects of N. sativa for the treatment of acne vulgaris, melanoma, vitiligo, atopic dermatitis, plaque psoriasis, and wound healing.
Mahin Alamgir MD,Marielle Jamgochian MBS,Jennifer Cucalon BS,Shazli Razi MD,Banu Farabi MD,Babar Rao MD
doi : 10.1111/ijd.15922
Volume 60, Issue 12 p. e500-e501
Daniele T. Abe MD,Carolina L. Sampaio MD,Karoline F. Pacheco MD,Paola C. V. da R. Passos MD,Janyana M. D. Deonizio MD, PhD
doi : 10.1111/ijd.15613
Volume 60, Issue 12 p. e501-e502
Adrian Michel Joseph Bailey BSc,Heidi Oi-Yee Li MD,Sophia Colantonio MD,MPH
doi : 10.1111/ijd.15781
Volume 60, Issue 12 p. e502-e504
Eduardo Rozas-Muñoz MD,Macarena Rosenblut MD,Nelson Ramos-Arancibia MD,Nicolas Hermosilla MD,José R Valbuena MD,Juan-Andres Madariaga MD
doi : 10.1111/ijd.15799
Volume 60, Issue 12 p. e504-e506
Yimei Tan MS,Yulong Tang BS,Weilin Pu PhD,Wencai Jiang MD,Yafei Xu MD,Wei Liu MD, PhD,Jiucun Wang PhD,Ou Qin MD,Yanyun Ma PhD
doi : 10.1111/ijd.15758
Volume 60, Issue 12 p. e506-e509
Dorine Canu MD,Jean-François Viallard MD, PhD,Estibaliz Lazaro MD, PhD,Marie-Sylvie Doutre MD, PhD
doi : 10.1111/ijd.15553
Volume 60, Issue 12 p. e509-e511
Dario Didona MD,Manfred Wolter MD,Rüdiger Eming MD,Hazem A. Juratli MD
doi : 10.1111/ijd.15856
Volume 60, Issue 12 p. e511-e512
Riti Bhatia MD,Tanvi Dev MD,Devasenathipathy Kandasamy MD,Sudhir Arava MD,Gomathy Sethuraman MD
doi : 10.1111/ijd.15626
Volume 60, Issue 12 p. e512-e514
Tutyana Sanusi MD,Retno I. Widayati MD,Puguh Riyanto MD,Diah Adriani Malik MD,Asih Budiastuti MD
doi : 10.1111/ijd.15712
Volume 60, Issue 12 p. e514-e516
Do you want to add Medilib to your home screen?